Simple test may predict who can handle tough cancer therapy
NCT ID NCT07309497
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a quick, practical geriatric assessment—looking at mobility, memory, self-care, and nutrition—can predict severe side effects in patients 65 and older who are about to receive CAR-T cell or bispecific antibody therapy for blood cancers like multiple myeloma or lymphoma. The goal is to help doctors and patients make more informed decisions and improve quality of life. The study will follow 208 participants and track toxicity, hospital stays, and functional changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a standard pre-treatment check that helps doctors better predict risks and improve quality of life for older patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find a clear link between the assessment and outcomes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BISPECIFIC ANTIBODY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inselspital Bern
RECRUITINGBern, Switzerland
-
Universitätsspital Zürich
RECRUITINGZurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?